ALDH7A1 and fragile X syndrome: IBMX and other xanthine-derived PDE inhibitors are also well-known adenosine receptor antagonists, consequently increasing cAMP production, which could also be a mode of action as it is “hypoactive” in FXS (Daly et al., 1981; Morgan et al., 1993).